Related Experiment Video

Updated: Aug 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Non-viral vectors for cancer therapy

Yasufumi Kaneda1, Yasuhiko Tabata

  • 1Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. kaneday@gts.med.osaka-u.ac.jp

Cancer Science
|April 25, 2006
PubMed

Insights

Gene therapy offers potential for cancer treatment but faces challenges. This review focuses on recent advancements in non-viral vectors for effective cancer gene therapy delivery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cancer remains a significant global health challenge, often exhibiting resistance to conventional therapies.
  • Gene therapy presents a promising avenue for cancer treatment, yet its clinical translation is hindered by various obstacles.
  • Effective delivery of therapeutic genes is critical for successful gene therapy outcomes.

Purpose of the Study:

  • To review recent advancements in the development of non-viral vectors for cancer gene therapy.
  • To discuss the advantages and limitations of various gene transfer methods in the context of cancer treatment.
  • To highlight improvements in non-viral vector design for enhanced gene delivery efficacy.

Main Methods:

  • Literature review of recent research on non-viral vectors for cancer gene therapy.
  • Analysis of different non-viral vector systems, including their design and application.
  • Comparative assessment of viral and non-viral gene delivery strategies.

Main Results:

  • Non-viral vectors are continually being improved for safer and more efficient gene delivery in cancer.
  • Recent developments focus on overcoming challenges such as cellular barriers and immune responses.
  • Optimized non-viral vectors show potential for targeted delivery and improved therapeutic efficacy.

Conclusions:

  • Non-viral vectors are crucial for the future of cancer gene therapy due to their safety profile and versatility.
  • Continued innovation in non-viral vector design is essential to realize the full potential of gene therapy for cancer treatment.
  • Addressing current limitations will pave the way for more effective gene-based cancer therapeutics.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...